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Abstract
Lung cancer is among the most lethal malignancies with a high metastasis and recurrence rate. Recent studies indicate that
tumors contain a subset of stem-like cancer cells that possess certain stem cell properties. Herein, we used Hoechst 33342
dye efflux assay and flow cytometry to isolate and characterize the side population (SP) cells from human lung cancer cell
line NCI-H460 (H460). We show that the H460 SP cells harbor stem-like cells as they can readily form anchorage-
independent floating spheres, possess great proliferative potential, and exhibit enhanced tumorigenicity. Importantly, the
H460 SP cells were able to self-renew both in vitro and in vivo. Finally, we show that the H460 SP cells preferentially express
ABCG2 as well as SMO, a critical mediator of the Hedgehog (HH) signaling, which seems to play an important role in H460
lung cancer cells as its blockage using Cyclopamine greatly inhibits cell-cycle progression. Collectively, our results lend
further support to the existence of lung cancer stem cells and also implicate HH signaling in regulating large-cell lung
cancer (stem) cells.
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Introduction
It has long been appreciated that most tumors are heteroge-
neous containing a spectrum of phenotypically different cell types.
Work in the past decade indicates that various human solid tumors
also contain functionally divergent tumor cells with subpopulations
possesing high tumorigenic potential and being able to reconstitute
the phenotypic and histologic heterogeneity of the parent tumor
when transplanted in immunodeficient mice. Such subsets of
tumor cells that possess enhanced tumorigenic capacity have been
operationally called tumor-initiating cells or cancer stem cells
(CSC), which have now been reported in most solid tumors [1,2].
Most CSCs have been identified, enriched, and purified using
either cell surface marker(s), among which CD44 and CD133 are
the most popular, or functional assays, which include side
population (SP) [3–6] and Aldeflour assays [7,8]. The SP strategy
was initially developed to enrich hematopoietic stem cells [3] and
is based on the ability of stem cells, which overexpress detoxifying
cell surface pumps ABCG2 and MDR1 (i.e., P-glycoprotein), to
efficiently efflux the cell-permeable dye Hoechst 33342 and
consequently, on dual wavelength FACS plot to present as a
Hoechst-negative population on the ‘side’ (or at the tail). The
Aldeflour assay, on the other hand, takes advantage of stem cells
overexpressing detoxifying enzymes aldehyde dehydrogenases
(ALDH) [7,8] and therefore, the CSC-enriched population can
more efficiently metabolize an experimental ALDH substrate to
release more fluorophore.
Lung cancer is the most lethal maligancy world-wide. Work in
the past several years indicates that both small-cell (SCLC) and
non-small cell (NSCLC) lung cancers contain stem-like cancer cells
[9–29]. As in most other tumors, ‘lung CSCs’ have been enriched
and purified using cell surface markers CD44 or CD133 or using
the two functional assays mentioned above. These lung CSCs have
been demonstrated to possess high clonal, clonogenic, and
frequently, tumorigenic potential and to be generally resistant to
therapeutic treatments. The lung cancer stem cells have been
reported in long-term cultures as well as in xenografts and primary
patient tumors. Of interest, a recent study using genetic mouse
models of lung cancer shows that lung tumors with different
genetic backgrounds have distinct CSC phenotypes [30], raising
the possibility that different patient lung tumors may have different
CSC phenotypes. Although the SP technique has been employed
to demonstrate CSCs in several lung cancer cell lines
[10,11,13,25], it is not known whether all patient tumor-derived
lung cancer cell lines possess a SP that is enriched in stem-like
cancer cells. Here we further address this question by using the
human large-cell large carcinoma line NCI-H460 (H460) and our
results reveal that H460 cells possess a SP that is enriched in
tumor-initiating cells.
Results and Discussion
Cultured human lung cancer cell line NCI-H460 has a SP
We first stained H460 cells with Hoechst 33342, which is
actively extruded by verapamil-sensitive ABC transporters in stem
cells [3]. When we observed the stained cells under a fluorescence
microscope, the majority of nuclei, as expected, appeared blue;
however, a small number of nuclei were negative for Hoechst
staining (Fig. 1, A and B; the arrows point to a Hoechst-negative
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cytometry [3–6,10,11,13,25]. We detected, in multiple indepen-
dent H460 cultures, a SP of 3.8060.5% (n=9), as illustrated in
Fig. 1C. Importantly, the SP was completely eliminated in the
presence of verapamil (Fig. 1D), a calcium-channel blocker and a
specific inhibitor of ABCG2 and MDR1 used in the clinical
treatment of lung cancer [31], indicating the specificity of the SP
we detected in H460 cells.
SP cells demonstrate high proliferative potential and can
self-renew
Up to now most stem-like cells have been demonstrated to
have an ability to form free-floating spheres in anchorage-
independent conditions [4–6,10,11,13]. Furthermore, CSCs have
been reported to possess a high proliferative potential. To
determine whether the H460 SP cells have similar CSC-
associated properties, we first cultured purified SP and non-SP
cells in serum-free condition (see Methods). We observed that the
H460 SP cells formed typical floating spheres with an efficiency
of 4.860.1% (Fig. 2A) whereas the non-SP cells mostly showed
adherent growth pattern (Fig. 2B) with much lower sphere-
forming capacity (0.860.3%). CCK-8 proliferation experiment
(see Method) also revealed higher proliferative potential in the SP
cells compared to the non-SP cells (Fig. 2C). When the primary
SP cell-derived spheres were dissociated and passaged, they
readily formed secondary spheres (data not shown). When
dissociated primary SP spheres were cultured in complete
medium containing fetal bovine serum (FBS) for one week, new
SP cells (6.260.8%) were detected with the majority cells being
non-SP cells (Fig. 3A). Again, the SP phenotype was completely
blocked in the presence of verapamil (Fig. 3B). These results
suggest that SP cells can self-renew in vitro.
The H460 SP cells demonstrate higher tumorigenicity
than corresponding non-SP cells
The gold standard for assaying CSC properties is to perform
limiting-dilution tumor transplantation experiments [1,2] and to
compare tumorigenicity, commonly measured by tumor inci-
dence, latency (i.e., the time between tumor cell implantation to
when tumors can first be palpated), growth rate (i.e., tumor
volume), and the endpoint tumor weight. We purified the H460
SP and non-SP cells and injected increasing numbers of cells in
Matrigel subcutaneously (s.c) into the nonobese diabetic/severe
combined immunodeficiency (NOD/SCID) mice (Fig. 4A). We
found that the SP cells overall showed higher tumorigenicity than
non-SP cells. For example, the SP cells regenerated tumors at the
lowest cell number (i.e., 5,000) implanted whereas the non-SP cells
did not regenerate any tumor at this cell dose (Fig. 4A). The SP
cells regenerated 6/6 tumors (i.e., 100%) whereas the non-SP cells
gave rise to 4/6 tumors (67%; P=0.039, Chi-Square tests). In
addition, the SP cells established tumors with a shorter latency
than the corresponding non-SP cells (Fig. 4A; P=0.007).
Furthermore, the H460 SP cell-derived tumors grew faster leading
to much larger tumors than non-SP cell derived tumors (Fig. 4A–
C; P,0.01). Histologically, the regenerated xenograft tumors had
morphological characteristics of the large-cell lung cancer. In
particular, the SP tumors displayed abundance of cells and mitotic
figures and showed evident capsular invasion (Fig. 4D, left). In
contrast, the non-SP tumors exhibited more necrotic areas
(Fig. 4D, right).
It was surprising and potentially interesting that the non-SP
cells, at 50,000 and 100,000, also regenerated tumors although the
tumors were smaller (Fig. 4B–C). Since the non-SP cells did not
form tumors at 5,000 cells (Fig. 4A), the easiest explanation would
be that the non-SP cell population might be contaminated with a
Figure 1. SP analysis in cultured H460 lung cancer cells. A–B, Hoechst staining of H460 cells. Note that although the majority of cells were
stained in the nucleus, some cells (indicated by arrows) apparently lacked nuclear Hoechst staining. C–D, SP phenotypes in the absence (C) or
presence (D) of verapamil.
doi:10.1371/journal.pone.0033358.g001
Side Population and Lung Cancer Stem Cells
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33358small number of SP cells, which would give rise to tumors when
large numbers of non-SP cells were implanted. Alternatively, non-
SP cells might be able to ‘de-differentiate’ back to SP cells at a low
rate such that in vivo some non-SP cells were converted into SP
cells, which then gave rise to tumors. This latter scenario was
recently demonstrated by others in several cultured tumor cell
systems [32]. To begin exploring these different possibilities, we
analyzed the SP composition in both SP and non-SP cell derived
H460 tumors. We observed that the SP tumors contained
8.460.6% SP cells (Fig. 3C–D) whereas the non-SP tumors
contained 1.460.2% SP cells (Fig. 3E–F). Although these results
could not definitely distinguish contamination from conversion,
they did provide an explanation for why the non-SP cells still gave
rise to tumors – it was because the non-SP tumors contained SP
cells.
The stem cell markers ABCG2 and SMO are highly
expressed in SP cells
The SP phenotype in hematopoietic stem cells is mediated
primarily by ABCG2 with some involvement of MDR1 or multi-
drug resistance protein 1 [31]. Many CSC-enriched SP’s
overexpress ABCG2 [4,6]. We therefore analyzed ABCG2 mRNA
levels and observed that, compared to regular FBS-cultured
monolayer H460 cells (Fig. 5A, lane 1), both spheres (Fig. 5A, lane
2) and purified SP cells (Fig. 5A, lane 3) expressed significantly
increased ABCG2 mRNA levels whereas purified non-SP H460
cells virtually lacked ABCG2 expression (Fig. 5A, lane 4). Likewise,
the SP tumors (Fig. 5A, lane 7) also expressed higher levels of
ABCG2 than corresponding non-SP tumors (Fig. 5A, lane 8). A
quantitative presentation was shown in Fig. 5B.
Tumorigenic lung cancer cells including SP cells have been
shown to preferentially express self-renewal molecules such as Oct-
4, Nanog, Bmi-1, and c-Kit [14,16,17,22,29], Notch signaling
components [18,28], and Wnt/b-catenin [23]. Emerging evidence
suggests that the Hedgehog (HH) signaling pathway may also be
intimately involved in lung cancer development and progression
[33,34]. Activation of HH signaling requires the transmembrane
protein Smoothened (SMO) as a critical mediator of the HH
signaling [35] and ABCG2 may act in the upstream regulation of
the Hh signaling pathway to protect the stemness of the SP
compartment [36]. We therefore determined the mRNA levels of
SMO in the same set of samples that were used for ABCG2
analysis. Strikingly, very much like ABCG2, the SMO mRNA
levels were significantly elevated in H460 spheres, SP cells, and SP
cell-derived tumors (Fig. 5A–B). To our knowledge, this finding
may represent the very first to link SMO overexpression to CSC-
enriched lung cancer cells.
The SMO inhibitor Cyclopamine inhibits H460 cell
proliferation
HH signaling pathway has been implicated in the maintenance
of stem or progenitor cells in many adult tissues. This pathway
regulates cell proliferation, tissue polarity, and cell differentiation
during normal development. Importantly, abnormal HH pathway
activation, such as high-levels of SMO expression, may play a role
in the maintenance of the capacity of tumor stem cells, favoring
self-renewal, and proliferation of their progeny [36,37]. To
determine whether HH signaling plays a role in H460 cells, we
employed Cyclopamine, a steroidal alkaloid that inhibits SMO
activity. As a control for Cyclopamine, we used a structurally
Figure 2. Sphere formation and proliferative capacity of H460 SP and non-SP cells. A–B, Purified SP and non-SP cells were cultured in
serum-free medium in anchorage-independent conditions. The SP cells formed typical floating spheres within 4 days (A) whereas the non-SP cells
largely established adherent growth (B). C, The SP cells displayed higher proliferative ability than non-SP cells as determined by CCK-8 kit (P,0.05 for
all time points, Student t-test).
doi:10.1371/journal.pone.0033358.g002
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and HH signaling. Compared to Tomatidine, Cyclopamine
appeared to reduce the low endogenous levels of SMO mRNA
(Fig. 5A, lanes 5 and 6). Compared to the vehicle control and
Tomatidine group, Cyclopamine dose- and time-dependently
inhibited the growth of H460 cells when used at 2–40 mmol/L
(Fig. 6A–E). Cell-cycle analysis demonstrated that Cyclopamine, at
20 mmol/L, time-dependently caused H460 cells to arrest in the
G1/S phase of the cell cycle (Fig. 6F). Specifically, Cyclopamine
treatment increased the G1 cells from ,71% at 24 h to ,93% at
96 h whereas decreased S-phase cells from 18% at 24 h to 2% at
96 h (Fig. 6F). At 96 h, slightly increased apoptosis (i.e., ,2%) was
also observed (Fig. 6F). It should be noted that both vehicle and
Tomatidine control groups also showed time-dependent increases
in G1-phase cells and time-related decreases in S-phase cells
(Fig. 6F), likely due to the fact that all cells were cultured for up to
96 h without replenishing media. Hence, exhaustion of growth
factors and nutrients caused partial cell-cycle arrest in the control
groups. Together, these results demonstrate that the HH signaling
is vital in H460 cells and blockade of HH signaling dramatically
causes cell-cycle arrest. Since SMO is preferentially expressed in
CSC-enriched SP and spheres(Fig. 5), we surmise that the HH
signaling imposes its effects likely on the lung CSCs.
In summary, in this study we present evidence that the H460
human large-cell lung carcinoma cell line contains a detectable SP.
Further, we show that the H460 SP cells harbor stem-like cells as
they can readily form anchorage-independent floating spheres,
possess great proliferative potential, and exhibit enhanced tumor-
regenerating capacity. Importantly, the H460 SP cells seem to be
able to self-renew in vitro (evidenced by replating sphere cells in
regular culture medium; Fig. 3A) and in vivo (evidenced by the SP
tumors containing a small percentage of SP cells with the majority
being non-SP cells; Fig. 3C). Finally, we show that the H460 SP
cells preferentially express ABCG2 as well as SMO, a critical
Figure 3. SP re-analysis in various samples. A–B, SP re-analysis when the SP spheres were disaggregated and dissociated cells cultured in
normal serum-containing medium for one week. C–D, SP re-analysis in the SP cell-derived tumors. E–F, SP re-analysis in non-SP cell-derived tumors. A,
C, E, without verapamil. B, D, F, with verapamil.
doi:10.1371/journal.pone.0033358.g003
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role in H460 lung cancer cells as its blockage using Cyclopamine
greatly inhibits cell-cycle progression. Collectively, our results
provide further support to the presence of stem-like cancer cells in
cultured lung cancer cell lines and also implicate HH signaling in
regulating large-cell lung cancer (stem) cells.
Figure 4. High tumorigenicity in SP cells. A, Table presentation of the tumorigenic potential of H460 SP and non-SP cells. Three parameters of
tumorigenicity, i.e., tumor incidence, latency, and volume (*P,0.01) were shown. All animals were terminated (term.) 28 days after implantation. B,
The SP cells regenerated larger tumors than corresponding non-SP cells at every cell dose. C, Gross tumor images when tumors were harvested at day
28 after s.c. injection of the SP and non-SP cells into NOD/SCID mice. D, Representative HE-stained photomicrographs of SP and non-SP tumors.
doi:10.1371/journal.pone.0033358.g004
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Ethics statement
ALL experiments were conducted according to the Institutional
Ethical Guidelines. All animal-related studies were approved by
the Tongji University Institutional IACUC committee. NOD/
SCID mice (the permit number: SYXK20070005) at SPF level
were used for tumor cell implantation experiments in this study.
All other studies presented herein were investigator-initiated and
did not require approval from other regulatory bodies.
Cell lines and animals
Human large-cell lung carcinoma cell line NCI-H460 was
bought from the Shanghai Institutes for Biological Sciences, CAS
(Shanghai, China) and maintained in medium recommended by
ATCC. All media were supplemented with 1% penicillin/
streptomycin and 10% fetal bovine serum (FBS; Invitrogen-Life
Technologies). Cells were incubated in a humidified incubator at
37uC supplied with 5% CO2. Cells were routinely maintained in
75-cm
2 tissue culture flasks (Corning Incorporated, USA) and
harvested using 0.25% trypsin when they were in logarithmic
phase of growth for SP analysis. The nonobese diabetic/severe
combined immunodeficiency (NOD/SCID) mice were purchased
from the Shanghai SLAC Laboratory Animal Co. Ltd.
SP analysis
The basic protocol was based on Goodell et al [3]. Briefly, the
NCI-H460 Cells were resuspended at 1610
6/mL in pre-warmed
DMEM (Invitrogen-Life Technologies). Hoechst 33342 dye was
added at a final concentration of 5 mg/mL in the presence or
absence of verepamil (50 mmol/L; Sigma) and the cells were
incubated at 37uC for 90 min with intermittent shaking. At the
end of the incubation, the cells were washed with ice-cold HBSS
(Invitrogen-Life Technologies), centrifuged down at 4uC, and
resuspended in ice-cold HBSS. Propidium iodide (Sigma) at a final
concentration of 2 mg/mL was added to the cells to gate viable
cells. The cell preparations were filtered through a 40-mm cell
strainer to obtain single cell suspension. Flow cytometric analyses
and sorting were performed on a Fluorescence Activated Cell
Sorter (FACS, Beckman Coulter Epics Altra).
Tumor cell implantation experiments
FACS-purified SP and non-SP H460 cells were mixted with
Matrigel (Becton Dickinson), and then subcutaneously (s.c) injected
into NOD/SCID mice. Groups of mice were inoculated with SP




Tumor growthwasmonitoredon weeklybasis andindividualtumor
volumes were measured using a digital caliper and approximated
accordingto the formula V=1/2ab
2 (a being the long diameter and
b the short diameter of the tumor). At the end of experiments, mice
were sacrificed after 4 weeks and tumors harvested, measured, and
photographed. The internal organs such as lung and liver were
carefully observed for metastasis nodules and tumor sections were
scrutinizedunder the microscope.Finally, tumorswerealsodigested
to make single-cell suspension for SP re-analysis.
Sphere formation assays in serum-free cultures
The SP and non-SP cells were cultured in serum-free DMEM-
F12 (Invitrogen-Life Technologies), supplemented with 20 ng/mL
epidermal growth factor (EGF), 10 ng/mL basic fibroblast growth
factor (bFGF), 5 mg/mL insulin (all from Sigma). Cells (1000/well)
were plated in 96-well culture dishes in 200 mL of growth medium
and 20 mL of medium per well was added every 2 days. The
number of spheres (W.150 mm) for each well was evaluated after
5 days of culture.
RT-PCR analysis
Cells were harvested and total RNA was extracted and prepared
for RT-PCR by using a PrimeScript
TM RT-PCR Kit (Takara,
Kyoto, Japan). Cycle parameters for ABCG2, SMO, and GAPDH
cDNAs were 30 sec at 94uC, 30 sec at 58uC (for ABCG2 and
GAPDH) or 55uC (for SMO), and 45 sec at 72uC for 35 cycles,
respectively. The primers for RT–PCR were as follows: ABCG2
(F) 59-CACCTTATTGGCCTCAGGAA-39, ABCG2 (R) 59-
CCTGCTTGGAAGGCTCTATG-39, SMO (F) 59-TTACCTT-
CAGCTGCCACTTCTACG-39, SMO (R) 59-GCCTTGGCA-
ATCATCTTGCTCTTC-39, GAPDH (F) 59-ACGACCACTTT-
GTCAAGCTC-39, and GAPDH (R) 59-GGTCTACATGGCA-
ACTGTGA-39.
Cell proliferation Assay
Cell proliferation assays were performed using the Cell
Counting Kit-8 (CCK-8, Dojindo, Kumamoto, Japan). Cells were
plated in 96-well plates at 5610
4 cells per well and cultured in the
growth medium. Cyclopamine and Tomatidine (all from Sigma)
were added, respectively, at a concentration of 20 mmol/L and
appropriate growth medium was added in control samples. CCK-
8 was added in each well at 24, 48, 72 and 96 h, and, after an
additional 4-h culture, the absorbance of each well was
determined and growth curve was plotted. The cell-cycle profiles
were analyzed by flow cytometry.
Statistical analysis
Data were generally presented as the mean 6 S.D and statistical
differences between experimental groups were analyzed by
Figure 5. RT-PCR analysis of ABCG2 and SMO mRNA levels. A,
Representative RT-PCR gel images. M, marker; lane 1, NCI-H460 cells
normally cultured in serum-containing medium; lane 2, the H460
spheres; lane 3, purified SP cells; lane 4, purified non-SP cells; lane 5, the
Tomatidine control group; lane 6, the Cyclopamine experimental group;
lane 7, SP tumors; lane 8, non-SP tumors. B, Quantitative presentation of
ABCG2 and SMO mRNA levels as determined by densitometry (P,0.001,
except ABCG2 mRNA lane 6 vs. lane 8 and SMO mRNA lane 1 vs. lane 5
and lane 4 vs. lane 6).
doi:10.1371/journal.pone.0033358.g005
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statistical software SPSS11.5 and according to the nature of data
analyzed. A P,0.05 was considered statistically significant in all
cases.
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Figure 6. Cyclopamine inhibits H460 cell proliferation. A–C, Representative photomicrographs of H460 cells 72 h after treatment with vehicle
control (A), Tomatidine (B), or Cyclopamine (C). Original maginifications: 6200. D, Cyclopamine dose-dependently inhibited H460 cell proliferation
(P,0.05; one-way ANOVA). E, Time course of Cyclopamine inhibition of H460 cells (P,0.05, one-way ANOVA). Cyclopamine was used at 20 mmol/L. F,
Effects of Cyclopamine on the cell cycle of H460 cells.
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